Arrowstreet Capital
RLMD icon

Arrowstreet Capital’s Relmada Therapeutics RLMD Stock Holding History

Arrowstreet Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,420
Closed -$75K – 1492
2022
Q4 		$75K Buy
+21,420
New +$188K ﹤0.01% 1299

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's RLMD Position: Q1 2023 in Review

Arrowstreet Capital sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 21,420 shares — an estimated $75K sold.

Arrowstreet Capital first reported a position in RLMD in Q4 2022 and held it in 1 quarter. The position peaked at $75K in Q4 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Arrowstreet Capital reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Arrowstreet Capital sold 21,420 Relmada Therapeutics shares in Q1 2023, an estimated $75K.
  • Arrowstreet Capital first reported a position in Relmada Therapeutics in Q4 2022 and held it in 1 quarter.
  • Arrowstreet Capital's Relmada Therapeutics position peaked at $75K in Q4 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Arrowstreet Capital's 13F filing for Q1 2023, filed 15 May 2023.